SCHEMBL4616119

SCHEMBL4616119

O=S(=O)(NCCO)c1cc(S(=O)(=O)c2ccccc2)ccc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.57
SLC12A2 P55011 1/20 0.57
SLC12A5 Q9H2X9 1/20 0.57
GSTO1 P78417 1/20 0.54
SFRP1 Q8N474 4/20 0.53
GLA P06280 1/20 0.52
CYP2C19 P33261 2/20 0.50
ALDH1A1 P00352 4/20 0.47
GAA P10253 2/20 0.47
PKM P14618 2/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA3 P07451 1/20 0.46
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46
CA5A P35218 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA13 Q8N1Q1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4616206 0.85 SFRP1 (0.73) LMNASLC12A2SLC12A5SFRP1GLA
SCHEMBL19392403 0.84 ALDH1A1 (0.60) LMNASFRP1CYP2C19ALDH1A1GAA
SCHEMBL4617973 0.83 LMNA (0.53) LMNASLC12A2SLC12A5SFRP1GLA
SCHEMBL4616651 0.83 TDP1 (0.66) LMNASLC12A2SLC12A5SFRP1GLA
SCHEMBL4618477 0.82 LMNA (0.52) LMNASLC12A2SLC12A5SFRP1GLA
SCHEMBL4615560 0.82 POLB (0.56) LMNASLC12A2SLC12A5SFRP1GLA
SCHEMBL4617968 0.81 LMNA (0.53) LMNASLC12A2SLC12A5SFRP1GLA
SCHEMBL4618609 0.81 SFRP1 (0.58) SFRP1
SCHEMBL4618473 0.80 LMNA (0.49) LMNASLC12A2SLC12A5GSTO1SFRP1
SCHEMBL4618655 0.80 LMNA (0.56) LMNASLC12A2SLC12A5SFRP1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 LMNA 4608/4885SLC12A2 1974/4885SLC12A5 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.